NorthStar Medical Radioisotopes, along with Wilmette, Ill.-based Monopar Therapeautics, have partnered with IsoTherapeutics Group to develop and manufacture Radio-Immuno-Therapeutics (RITs) for the potential treatment of severe COVID-19, the company announced recently….

NorthStar Medical Radioisotopes is collaborating with Monopar Therapeutics, a clinical-stage biopharmaceutical company, to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19, the company announced recently. “NorthStar will apply its expertise…

NorthStar Medical Radioisotopes received approval from the U.S. Food and Drug Administration (FDA) the addition of two molybdenum-99 (Mo-99) filling lines at its facility in Columbia, Mo., the company announced…

NorthStar Medical Radioisotopes and Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, have signed a letter of intent for the commercial supply of copper-67 as an…

NorthStar Medical Radioisotopes and Purdue University’s College of Pharmacy signed a collaborative agreement, which expands the College of Pharmacy’s nuclear pharmacy training program, the company announced recently. “We are excited…

NorthStar Medical Radioisotopes has been awarded $15 million in a cooperative agreement with the U.S. Department of Energy’s National Nuclear Security Administration (DOE/NNSA), the company announced today. According to a…

SHINE Medical Technologies and NorthStar Medical Radioisotopes are part of a list of four companies to begin negotiations for potential new cooperative agreement awards on the production of Molybdenum-99 (Mo-99) with the…

NorthStar Medical Radioisotopes announced recently that it earned approval from the U.S. FDA for a facility in Beloit, Wis., to manufacture its RadioGenix System and associated materials. According to a…